Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Copenhagen University Hospital, Hvidovre | OTHER |
Not provided
Not provided
Not provided
Not provided
Co-infusion of Neurotensin and GLP-1 Effects on Appetite and Food Intake.
Neurotensin (NT), a gut hormone and neuropeptide, and GLP-1, as well a gut hormone, increases in circulation after bariatric surgery in rodents and humans and inhibit food intake in mice.
Studies in rodents have shown that a GLP-1 receptor agonist and long acting neurotensin inhibit food intake.
This study investigates whether the synergistic anorexic effects of neurotensin and GLP-1 agonism suggested by animal studies can be translated.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Saline+Saline | Other |
| |
| Neurotensin+Saline | Other |
| |
| GLP-1+Saline | Other |
| |
| Neurotensin + GLP-1 | Other |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Saline + saline | Other | Double saline infusion followed by an ad libitum meal |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Ad-libitum food intake | Neurotensin (NT), saline, GLP-1 and GLP-1+Neurotensin will be infused on four occasions in random order, double blinded. After 2h of infusion an ad libitum meal will be served. When the meal is completed food intake will be determined by weighing the leftovers. | 120 min |
| Measure | Description | Time Frame |
|---|---|---|
| Appetite and gastrointestinal sensations | Using visual analogue scales (VAS) the effect of infusions and meals will be documented. Ad libitum meals will also be evaluated using VAS. | -60, -30, 0, 30, 60, 90, 120, 150 and 180 min |
| Plasma glucose |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Birgitte Holst, PhD, Professor | Contact | +4521487699 | holst@sund.ku.dk | |
| Sten Madsbad, DMsc, Professor | Contact | +4521691911 | sten.madsbad@regionh.dk |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Copenhagen, Department of Biomedical Scienses | Recruiting | Copenhagen | 2200 | Denmark |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009765 | Obesity |
| ID | Term |
|---|---|
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D012965 | Sodium Chloride |
| D009496 | Neurotensin |
| D052216 | Glucagon-Like Peptide 1 |
| ID | Term |
|---|---|
| D002712 | Chlorides |
| D006851 | Hydrochloric Acid |
| D017606 | Chlorine Compounds |
| D007287 | Inorganic Chemicals |
Not provided
Not provided
Participants will be studied on multiple occasions (4 days) in a randomised and double blinded fashion.
Not provided
Not provided
Participants will not be informed of the nature of the infusion they are administered on any of the study days. The investigator will be provided with an infusion (either isotonic saline with humane serum albumine (HSA) or isotonic saline with HSA + neurotensin or isotonic saline with HSA + GLP-1) prepared by a designated colleague
| Neurotensin + saline |
| Other |
Neurotensin + saline infusion followed by an ad libitum meal |
|
| GLP-1 + saline | Other | GLP-1 + saline infusion followed by an ad libitum meal |
|
| GLP-1 + Neurotensin | Other | GLP-1 + Neurotensin infusion followed by an ad libitum meal |
|
Bed-side measurements of plasma glucose
| -60, -30, 0, 15, 30, 45, 60, 90, 120, 150, 165 and 180 min |
| Neurotensin | Plasma analysis | -60, -30, 0, 15, 30, 45, 60, 90, 120, 150, 165 and 180 min |
| GLP-1 | Plasma analysis | -60, -30, 0, 15, 30, 45, 60, 90, 120, 150, 165 and 180 min |
| Insulin | Serum analysis | -60, -30, 0, 15, 30, 45, 60, 90, 120, 150, 165 and 180 min |
| C-peptide | Serum analysis | -60, -30, 0, 15, 30, 45, 60, 90, 120, 150, 165 and 180 min |
| Bile acids | Plasma analysis | -60, -30, 0, 15, 30, 45, 60, 90, 120, 150, 165 and 180 min |
| Ghrelin | Plasma analysis | -60, -30, 0, 15, 30, 45, 60, 90, 120, 150, 165 and 180 min |
| Peptide YY (PYY) | Plasma analysis | -60, -30, 0, 15, 30, 45, 60, 90, 120, 150, 165 and 180 min |
| Leptin | Plasma analysis | -60, -30, 0, 15, 30, 45, 60, 90, 120, 150, 165 and 180 min |
| Metabolomics | Plasma analysis | -60, -30, 0, 15, 30, 45, 60, 90, 120, 150, 165 and 180 min |
| Proteomics | Plasma analysis | -60, -30, 0, 15, 30, 45, 60, 90, 120, 150, 165 and 180 min |
| Copenhagen University Hospital Hvidovre | Recruiting | Copenhagen | 2650 | Denmark |
|
| D001835 |
| Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D017670 |
| Sodium Compounds |
| D009479 | Neuropeptides |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D009419 | Nerve Tissue Proteins |
| D011506 | Proteins |
| D004763 | Glucagon-Like Peptides |
| D052336 | Proglucagon |
| D005768 | Gastrointestinal Hormones |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |